The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Narkevich I.A.

St. Petersburg State Chemical Pharmaceutical University

Nemyatykh O.D.

St. Petersburg State Chemical Pharmaceutical University

Medvedeva D.M.

St. Petersburg State Chemical Pharmaceutical University

Akpaeva K.M.

St. Petersburg State Chemical Pharmaceutical University;
Astana Medical University

Sakipova Z.B.

Asfendiyarov Kazakh National Medical University

Shukirbekova A.B.

Astana Medical University

Mironenkova Zh.V.

St. Petersburg State Chemical Pharmaceutical University

Consumption of antiretroviral drugs in the Republic of Kazakhstan

Authors:

Narkevich I.A., Nemyatykh O.D., Medvedeva D.M., Akpaeva K.M., Sakipova Z.B., Shukirbekova A.B., Mironenkova Zh.V.

More about the authors

Journal: Medical Technologies. Assessment and Choice. 2022;44(2): 22‑32

DOI: 10.17116/medtech20224402122

Read: 1845 times

Download PDF (RU)
Contact the author
Table of contents

CONSUMPTION OF ANTIRETROVIRAL DRUGS IN THE REPUBLIC OF KAZAKHSTAN
CONSUMPTION OF ANTIRETROVIRAL DRUGS IN THE REPUBLIC OF KAZAKHSTAN

To cite this article:

Narkevich IA, Nemyatykh OD, Medvedeva DM, Akpaeva KM, Sakipova ZB, Shukirbekova AB, Mironenkova ZhV. Consumption of antiretroviral drugs in the Republic of Kazakhstan. Medical Technologies. Assessment and Choice. 2022;44(2):22‑32. (In Russ.)
https://doi.org/10.17116/medtech20224402122

Подписка 2026 Медицинские технологии. Оценка и выбор (Medical Technologies. Assessment and Choice)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

OBJECTIVE

To evaluate consumption of antiretroviral drugs in the Republic of Kazakhstan.

MATERIAL AND METHODS

We analyzed data of the analytical agency IQVIA for the period from 2014 to 2020. Comparative analysis methods, time series and ATC/DDD methodology were applied.

RESULTS

Analysis of the Kazakh and international practices of antiretroviral therapy suggests that certain drugs used abroad including nucleoside reverse transcriptase inhibitors (NRTIs), protease inhibitors (PIs), integrase inhibitors (IIs) and CCR5 receptor antagonists are not included in assortment matrix determining pharmacotherapy of HIV-infected patients in the Republic of Kazakhstan. Assessment of antiretroviral drug consumption indicates increase of therapy availability that is expressed in increment of the volume of realized demand in physical terms by 84% in the context of decrease in sales in value terms by 17%. Structuring of antiretroviral drug consumption by producing countries showed that foreign pharmaceutical companies (the United States in value terms (52%), India in natural units (62%)) make the maximum contribution to sale structure. Assessment of consumption in each pharmacotherapeutic group demonstrates predominance of combined ARV therapy containing 2 NRTIs and 1 NNRTI and combined therapy containing 2 NRTIs in physical terms and PI with II in value terms. The Republic of Kazakhstan complies with the WHO recommendations on minimizing the drug resistance of HIV to antiretroviral therapy.

CONCLUSION

The obtained results substantiate further research in improving the drug supply of patients with HIV infection aimed at expanding the national portfolio of antiretroviral drugs.

Keywords:

antiretroviral therapy
ATC/DDD methodology
drug provision
HIV-infection

Authors:

Narkevich I.A.

St. Petersburg State Chemical Pharmaceutical University

Nemyatykh O.D.

St. Petersburg State Chemical Pharmaceutical University

Medvedeva D.M.

St. Petersburg State Chemical Pharmaceutical University

Akpaeva K.M.

St. Petersburg State Chemical Pharmaceutical University;
Astana Medical University

Sakipova Z.B.

Asfendiyarov Kazakh National Medical University

Shukirbekova A.B.

Astana Medical University

Mironenkova Zh.V.

St. Petersburg State Chemical Pharmaceutical University

Received:

23.02.2022

Accepted:

30.03.2022

Close metadata

References:

  1. Deklaraciya General’noj assamblei OON ot 25 sentyabrya 2015 goda «Preobrazovanie nashego mira: Povestka dnya v oblasti ustojchivogo razvitiya na period do 2030 goda». Accessed February 10, 2022. (In Russ.). https://docs.cntd.ru/document/420355765
  2. VICH/SPID. VOZ. Informacionnye byulleteni. Accessed February 10, 2022. (In Russ.). https://www.who.int/ru/news-room/fact-sheets/detail/hiv-aids
  3. GBD 2017 HIV collaborators. Global, regional, and national incidence, prevalence, and mortality of HIV, 1980—2017, and forecasts to 2030, for 195 countries and territories: A systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017. Lancet HIV. 2019;6(12):831-859.  https://doi.org/10.1016/S2352-3018(19)30196-1
  4. Trapeznikova NA, Rostova NB, Loginova VV. Antiretroviral therapy: medicinal resources and their rational choice. Problemy sotsial’noi gigieny, zdravookhraneniya i istorii meditsiny. 2020;28(6):1355-1361. (In Russ.). https://doi.org/10.32687/0869-866X-2020-28-6-1355-1361
  5. Altice F, Evuarherhe O, Shina S, Carter G, Beaubrun AC. Adherence to HIV treatment regimens: a systematic literature review and meta-analysis. Patient Preference and Adherence. 2019;13:475-490.  https://doi.org/10.2147/PPA.S192735
  6. Degroote S, Vandekerckhove L, Vogelaers D, Bulcke CV. Patient-reported outcomes among people living with HIV on single-versus multi-tablet regimens: Data from a real-life setting. PLoS One. 2022;17(1):e0262533. https://doi.org/10.1371/journal.pone.0262533
  7. Cohen CJ, Molina JM, Cahn P, Clotet B, Fourie J, Grinsztejn B, et al.; ECHO Study Group; THRIVE Study Group. Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment naive HIV-1-infected patients: pooled results from the phase 3 double blind randomized ECHO and THRIVE Trials. Journal of Acquired Immune Deficiency Syndromes (1999). 2012;60(1):33-42.  https://doi.org/10.1097/QAI.0b013e31824d006e
  8. Medvedeva DM, Narkevich IA, Nemyatykh OD. Analysis of the availability of medicines for children in need of palliative care. Pharmacoeconomics. Farmakoekonomika. Sovremennaya farmakoekonomika i farmakoepidemiologiya. 2021;14(2):167-179. (In Russ.). https://doi.org/10.17749/2070-4909/farmakoekonomika.2021.094
  9. Rostova NB, Gudilina NA. Criteria of rational pharmacotherapy on the example of HIV infection. Voprosy virusologii. 2018;63(1):41-47. (In Russ.). https://doi.org/10.18821/0507-4088-2018-63-1-41-47
  10. Hollingworth S, Kairuz T. Measuring Medicine Use: Applying ATC/DDD Methodology to Real-World Data. Pharmacy (Basel, Switzerland). 2021;17;9(1):60.  https://doi.org/10.3390/pharmacy9010060
  11. Babii VV, Yagudina RI. The relevance of the pharmacoeconomical assessment of highly active antiretroviral therapy (HAART) in HIV-infected patients in the Russian Federation. Farmakoekonomika: teoriya i praktika. 2015;3(1):68. (In Russ.). https://doi.org/10.30809/phe.1.2015.32
  12. Narkevich IA, Nemyatykh OD, Timchenko VN, Siukaeva DD, Terninko TM, Alekseeva VA. Structural analysis of the range of medicines for etiopathogenetic therapy of children with acute viral infections. Formuly farmatsii. 2020;2(2):20-28. (In Russ.).
  13. Siukaeva DD, Narkevich IA, Nemyatykh OD, Basakina II. Analysis of hospital purchases of systemic antimicrobial drugs in the pharmaceutical market of the North-Western Federal District. Nauchnye vedomosti Belgorodskogo Gosudarstvennogo universiteta. Seriya: Meditsina. Farmatsiya. 2018;41(4):672-686. (In Russ.). https://doi.org/10.18413/2075-4728-2018-41-4-672-686
  14. Klinicheskij protokol diagnostiki i lecheniya VICH-infekcii u vzroslyh. Odobren Ob»edinennoj komissiej po kachestvu medicinskih uslug Ministerstva zdravoohraneniya Respubliki Kazahstan ot 11 iyunya 2020 goda. Accessed February 10, 2022. (In Russ.). https://itpcru.org/wp-content/uploads/2020/06/kazahstan-kp-vich-vzroslye-iyun-2020.pdf
  15. European AIDS Clinical Society Guidelines. Accessed February 10, 2022. https://www.eacsociety.org/media/final2021eacsguidelinesv11.0_oct 2021.pdf
  16. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. Accessed February 10, 2022. https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/whats-new-guidelines
  17. Zhang K, Zhang Y, Liu X, Li A, Gao M, Hou J, et al. Three-Drug Regimens Containing Integrase Inhibitor Show Good Efficacy and Safety in Treatment-Naive Patients with HIV-1: A Bayesian Analysis. Frontiers in Pharmacology. 2021;12:603068. https://doi.org/10.3389/fphar.2021.603068
  18. Rudakova AV. Pharmacoeconomics of Hiv Treatment with Fixed Dose Combinations of Antiretroviral Agents. VICH-infekciya i immunosupressii. 2014;6(1):97-100. (In Russ.).
  19. Kovaleva KA, Nemyatykh OD, Narkevich IA, Ratova LG, Parizhskaya EN, Konradi AO, Basakina II. Analysis of the range of medicines for the treatment of patients with stable angina in the Russian Federation. Meditsinskii Vestnik Bashkortostana. 2019;14(5):43-47. (In Russ.).
  20. Mironenkova ZhV, Davletianova AF, Gabdulkhakova LM, Il’inova YuG, Ivakina SN, Yapparov RG. A study of the availability of medicines for the treatment of HIV-infected patients in the Republic of Bashkortostan. VICH-infekciya i immunosupressii. 2019;11(1):96-102. (In Russ.). https://doi.org/10.22328/2077-9828-2019-11-1-96-102
  21. Tsitlionok EA, Narkevich IA, Nemyatykh OD, Siukaeva DD, Grinyuk AS, Lisachenko VO. Structural analysis of sales of medicines used for the treatment of chronic hepatitis C on the Russian market. Remedium. 2021;(3):28-34. (In Russ.).
  22. Kubaeva MB, GushchinaYuSh. Pharmaceutical analysis of the cost of anti-retroviral medicines, used in the treatment of HIV-infected patients. Pharmacoeconomics. Farmakoekonomika. Sovremennaya farmakoekonomika i farmakoepidemiologiya. 2017;10(2):41-43. (In Russ.) https://doi.org/10.17749/2070-4909.2017.10.2.041-043
  23. Mironenkova ZhV, Mussavi ME, Davlet’yanova AF. The main characteristics of ART in HIV-infected citizens of the Lebanese Republic. Zhurnal infektologii. 2017;9(3):109-116. (In Russ.). https://doi.org/10.22625/2072-6732-2017-9-3-109-116
  24. Rudakova AV. Cost analysis of the first line antiretroviral therapy in Russian Federation. Zhurnal infektologii. 2014;6(1):72-77. (In Russ.).
  25. Dowers E, Zamora F, Barakat LA, Ogbuagu O. Dolutegravir/rilpivirine for the treatment of HIV-1 infection. HIV AIDS (Auckland). 2018;10:215-224.  https://doi.org/10.2147/HIV.S157855
  26. Himmel DM, Arnold E. Non-Nucleoside Reverse Transcriptase Inhibitors Join Forces with Integrase Inhibitors to Combat HIV. Pharmaceuticals (Basel). 2020;13(6):122.  https://doi.org/10.3390/ph13060122
  27. Rostova NB, Ivanova ES, Ivanova YuN. Medical and social characteristics of HIV-infected patients receiving antiretroviral therapy. Klinicheskaya meditsina. 2015;93(3):52-56. (In Russ.). https://doi.org/10.24884/1607-4181-2016-23-4-25-28
  28. Ustojchivost’ VICH k lekarstvennym preparatam. VOZ. Informacionnye byulleteni. Accessed February 10, 2022. (In Russ.). https://www.who.int/ru/news-room/fact-sheets/detail/hiv-drug-resistance
  29. Yurin OG, Efremova OS. European and American recommendations for the treatment of HIV infection. Meditsinskii sovet. 2017;(4):67-72. (In Russ.). https://doi.org/10.21518/2079-701x-2017-4-67-72
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.